MICHELLE DAHLE: Open Payments
NPI 1225197379 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 46 payments from 18 companies in 2025. Trend: 2023 $1,074 · 2024 $981 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $142 |
| Lilly USA, LLC | 6 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $101 |
| AstraZeneca Pharmaceuticals LP | 5 | $77 |
| Astellas Pharma US Inc | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Novo Nordisk Inc | 2 | $49 |
| Inspire Medical Systems, Inc. | 2 | $47 |
| Alkermes, Inc. | 2 | $44 |
Products named: CAPLYTA, JARDIANCE, Veozah, MOUNJARO, QULIPTA, REXULTI, VRAYLAR, INSPIRE.
Industry payments across UT — which companies pay providers there.
